Showing results (11-20 of 17) with videos related to
Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
Blood|December 9, 2024
Acute resistance to BET inhibitors remodels compensatory transcriptional programs via p300 coactivationViral Shah, George Giotopoulos, Hikari Osaki, et al.Nature Cell Biology|August 22, 2017
Early loss of Crebbp confers malignant stem cell properties on lymphoid progenitorsSarah J Horton, George Giotopoulos, Haiyang Yun, et al.Blood Advances|September 12, 2024
Outcomes with single-agent gilteritinib for relapsed or refractory FLT3-mutant AML after contemporary induction therapyJad Othman, Angela Hwang, Maximillian Brodermann, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 9, 2022
A Phase I/II Open-Label Study of Molibresib for the Treatment of Relapsed/Refractory Hematologic MalignanciesMark A Dawson, Gautam Borthakur, Brian J P Huntly, et al.Blood Neoplasia|June 2, 2025
Real-world outcomes of newly diagnosed AML treated with venetoclax and azacitidine or low-dose cytarabine in the UK NHSJad Othman, Ho Pui Jeff Lam, Sarah Leong, et al.American Journal of Hematology|November 22, 2025
Effectiveness of Gilteritinib Beyond Second-Line Therapy in Relapsed/Refractory FLT3 -Mutated Acute Myeloid Leukemia: A Real-World Multicenter Study of 171 PatientsMatteo Molica, Gema Miralles, Richard Dillon, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 2, 2026
Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk ModelCurtis A Lachowiez, Joshua F Zeidner, Jad Othman, et al.Pageof 2